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Background
Cardiac aging is associated with altered myocardial struc-
ture and function that may contribute to the development
of heart failure (HF), particularly in the elderly. C-type
natriuretic peptide (CNP) is of endothelial cell origin and
represents the most potent anti-fibrotic peptide of the
natriuretic peptide (NP) family. CNP activates the NP
receptor-B (NPR-B), which is found in high abundance in
cardiac fibroblasts. Further, selective cardiac knockout of
NPR-B contributes to exaggerated cardiomyocyte hyper-
trophy in response to pressure overload. In addition, infu-
sion of CNP suppresses post-myocardial infarction (MI)
induced cardiac fibrosis in a rodent model of MI. The
impact of aging on circulating CNP and associated left
ventricular (LV) structure and function are undefined.
Objective
We hypothesized that a decrease in endogenous circulat-
ing CNP occurs with aging is associated with an increase
in cardiac fibrosis and altered LV function and structure.
Methods
Studies were performed in 2, 11 and 20 month old male
Fischer rats (n = 8/group). Standard echocardiography
was used to assess LV structure and function. Left ventri-
cles were harvested for gross and histopathologic analysis.
Plasma CNP and BNP were measured.
Results
Aging from 2 to 20 months in male Fischer rats (equiva-
lent to human aging from childhood to the 6th decade of
life) was associated with progressive reductions in plasma
CNP. Specifically, there was a significant incremental
decrease in plasma CNP in the 2 month old group (30 ±
3 pg/ml) to the 11 month old group (21 ± 1 pg/ml) to the
20 month old group (9 ± 1 pg/ml). Significant and pro-
gressive cardiac fibrosis was observed with aging (from
9% to 15% to 21%, p < 0.001) Importantly, LV interstitial
fibrosis, determined by picrosirius red staining, was
inversely correlated with plasma CNP levels. In contrast,
plasma BNP was slightly but significantly increased from
the 2 month old group to 20 month old group (21 ± 2 to
26 ± 1 pg/ml, p < 0.05). Finally, the decrease in plasma
CNP, seen from the 2 month old group to the 20 month
old group, was also associated with a significant reduction
in LV weight to body weight ratio (2.24 ± 0.02 to 1.79 ±
0.03, p < 0.001) and ejection fraction (88 ± 1% to 80 ±
1%, p < 0.001) and increases in LV end-diastolic chamber
diameter (6.61 ± 0.09 mm to 7.48 ± 0.09 mm, p < 0.001).
Conclusion
We report for the first time that aging is associated with a
progressive decline in circulating CNP and a progressive
increase in cardiac fibrosis and systolic dysfunction. Fur-
ther studies are warranted to explore the hypothesis that a
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mechanism of myocardial aging with altered LV structure
and function may include a decrease in the bioavailability
of the paracrine and autocrine cardiovascular hormone
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